Reciprocal paracrine interactions between tumour cells and endothelial cells: The 'angiogenesis progression' hypothesis

European Journal of Cancer Part A

Volumn 32, Issue 14, 1996, Pages 2438-2450

  Rak, J ^a   Filmus, J ^a   Kerbel, R S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; COLORECTAL CARCINOMA; ENDOTHELIUM CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; MUTANT; ONCOGENE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR GROWTH;

EID: 0030484797     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(96)00396-6     Document Type: Article

References (149)

1. 1. Potten CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metast Rev 1992, 11, 179-195.
2. WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995, 55, 2910-2919.
3. 3. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61, 759-767.
4. 4. Fearon ER. Molecular abnormalities in colon and rectal cancer. In Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, W.B. Saunders, 1995, 340-357.
5. 5. Prendergast GC, Gibbs JB. Pathways of ras function: connections to the actin cytoskeleton. Adv Cancer Res 1993, 62, 19-64.
6. 6. Kang J-S, Krauss RS. Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. Mol Cell Biol 1996, 16, 3370-3380.
7. 7. Winston JT, Coats SR, Wang Y-Z, Pledger WJ. Regulation of the cell cycle machinery by oncogenic ras. Oncogene 1996, 12, 127-134.
8. 8. Rak J, Mituhashi Y, Erdos V, Huang S-N, Filmus J, Kerbel RS. Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by expression of a mutant c-H-ras oncogene. J Cell Biol 1995, 131, 1587-1598.
9. 9. Rak J, Mitsuhashi Y, Bayko L, Filmus J, Sasazuki T, Kerbel RS. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995, 55, 4575-4580.
10. 10. Grugel S, Finkenzeller G, Weindel K, Barleon B, Marme D. Both v-Ha-ras and v-raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells. J Biol Chem 1995, 270, 25915-25919.
11. 11. St. Croix B, Florenes VA, Rak JW, et al. Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of tumor cells to anticancer agents. Nature Medicine, in press.
12. 12. Wang J, Walsh K. Resistance to apoptosis conferred by cdk inhibitors during myocyte differentiation. Science 1996, 273, 359-361.
13. 13. Rocha M, Kruger A, Van Rooijen N, Schirrmacher V, Umansky V. Liver endothelial cells participate in T-cell-dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo. Int J Cancer 1995, 63, 405-411.
14. WAF1 is required for survival of differentiating neuroblastoma cells. Mol Cell Biol 1996, 16, 1335-1341.
15. 15. Shim J, Lee H, Park J, Kim H, Choi E-J. A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. Nature 1996, 381, 804-807.
16. 16. Kinzler KW, Vogelstein B. Life (and death) in a malignant tumour. Nature 1996, 379, 19-20.
17. 17. Graeber TG, Osmanian C, Jacks T. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379, 88-91.
18. 18. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995, 36, 119-126.
19. 19. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 1994, 9, 963-969.
20. 20. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995, 55, 6161-6165.
21. 21. Van Meir EG, Polverini PJ, Chazin VR, Huang SH-J, Tribolet N, Cavanee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nature Genetics 1994, 8, 171-182.
22. 22. Ikeda E, Achen MG, Breier G, Risau W. Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells. J Biol Chem 1995, 270, 19761-19766.
23. 23. Finkenzeller G, Technau A, Marme D. Hypoxia-induced transcription of the vascular endothelial growth factor gene is independent of functional AP-1 transcription factor. Biochem Biophys Res Commun 1995, 208, 432-439.
24. 24. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359, 843-845.
25. 25. Shweiki D, Neeman M, Itin A, Keshet E. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci USA 1995, 92, 768-772.
26. 26. Stein I, Neeman M, Shweiki D, Itin A, Keshet E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes. Mol Cell Biol 1995, 15, 5363-5368.
27. 27. Alon T, Hemo I, Itin A, Pe'er J, Stone J, Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nature Medicine 1995, 1, 1024-1028.
28. 28. Takashashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55, 3964-3968.
29. 29. Takebayashi Y, Akiyama S-i, Yamada K, Akiba S, Aikou T. Angiogenesis as an unfavorable prognostic factor in human colorectal carcinoma. Cancer 1996, 78, 226-231.
30. 30. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1989, 82, 4-6.
31. 31. Thompson TC, Southgate J, Kitchener G, Land H. Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989, 56, 917-930.
32. 32. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during transition from hyperplasia to neoplasia. Nature 1989, 339, 58-61.
33. 33. Christofori G, Naik P, Hanahan D. Vascular endothelial growth factor and its receptors, flt-1 and flk-1, are expressed in normal pancreatic islets and throughout islet cell tumorigenesis. Mol Endocrinol 1995, 9, 1760-1770.
34. 34. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrun M, Folkman J, Hanahan D. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell 1991, 66, 1095-1104.
35. 35. Naik P, Karrim J, Hanahan D. The rise and fall of apoptosis during multi-stage tumorigenesis: down-modulation contributes to tumor progression from angiogenic progenitors. Genes Develop, in press.
36. 36. Parangi S, Dietrich W, Christofori G, Lander ES, Hanahan D. Tumor suppressor loci on mouse chromosomes 9 and 16 are lost at distinct stages of tumorigenesis in a transgenic model of islet cell carcinoma. Cancer Res 1995, 55, 6071-6076.
37. 37. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D, Kerbel RS. Oncogenes as inducers of tumor angiogenesis. Cancer Metast Rev 1995, 14, 263-277.
38. 38. Mukhopadhyay D, Tsiokas L, Zhou X-M, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995, 375, 577-581.
39. 39. Bortner DM, Langer SJ, Ostrowski MC. Non-nuclear oncogenes and the regulation of gene expression in transformed cells. Crit Rev Oncogen 1993, 4, 137-160.
40. 40. Derijard B, Hibi M, Wu I-H. JNK1: a protein kinase stimulated by UV light and H-ras that binds and phosphorylates the c-jun activation domain. Cell 1994, 76, 1025-1037.
41. 41. Folkman J. Tumor angiogenesis. In Mendelsohn J, Howley PM, Israel MA, Liotta LA, eds. The Molecular Basis of Cancer. Philadelphia, W.B. Saunders, 1995, 206-232.
42. 42. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987, 235, 442-447.
43. 43. Dvorak HF, Nagy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991, 3, 77-85.
44. v integrins. Science 1995, 270, 1500.
45. 45. Freeman MR, Schneck FX, Gagnon ML. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 1995, 55, 4140-4145.
46. 46. Hlatky L, Tsionou C, Hahnfeldt P, Coleman CN. Mammary fibroblasts may influence breast tumor angiogenesis via hypoxia-induced vascular endothelial growth factor up-regulation and protein expression. Cancer Res 1994, 54, 6083-6086.
47. 47. Rak J, St Croix B, Kerbel RS. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs 1995, 6, 3-18.
48. 48. Minamoto T, Sawaguchi K, Mai M, Yamashita N, Sugimura T, Esumi H. Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res 1994, 54, 2841-2844.
49. 49. Hasegawa H, Ueda M, Watanabe M, Teramoto T, Mukai M, Kitajima M. K-ras gene mutations in early colorectal cancer. . . flat elevated vs polyp-forming cancer . . . . Oncogene 1995, 10, 1413-1416.
50. 50. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260, 85-88.
51. 51. Plattner R, Anderson MJ, Sato KY, Fasching CL, Der CJ, Stanbridge EJ. Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells. Proc Natl Acad Sci USA 1996, 93, 6665-6670.
52. 52. Zhao J, Buick RN. Relationship of levels and kinetics of H-ras expression to transformed phenotype and loss of TGF-β-mediated growth regulation in intestinal epithelial cells. Exp Cell Res 1993, 204, 82-87.
53. 53. Filmus J, Robles AI, Shi W, Wong MJ, Colombo LL, Conti CJ. Induction of cyclin DI overexpression by activated ras. Oncogene 1994, 9, 3627-3633.
54. 1 progression in NIH 3T3 cells. Mol Cell Biol 1995, 15, 3654-3663.
55. 55. Tannock IF. Tumor growth and cell kinetics. In Tannock IF, Hill RP, eds. The Basic Science of Oncology. Toronto, Pergamon Press, 1995, 140-159.
56. 56. Bedi A, Pasricha PJ, Akhtar AJ. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995, 55, 1811-1816.
57. 57. Su Z-Z, Austin VN, Zimmer SG, Fisher PB. Defining the critical gene expression changes associated with expression and suppression of the tumorigenic and metastatic phenotype in Ha-ras-transformed cloned rat embryo fibroblast cells. Oncogene 1993, 8, 1211-1219.
58. 58. Filmus J, Shi W, Spencer T. Role of transforming growth factor alpha (TGF-α) in the transformation of ras-transfected rat intestinal epithelial cells. Oncogene 1993, 8, 1017-1022.
59. 59. Olive PL, Chaplin DJ, Durand RE. Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer 1985, 52, 739-746.
60. 60. Rak JW, Kerbel RS. Growth advantage ('clonal dominance') of metastatically-competent tumor cell variants expressed under selective two or three dimensional tissue culture conditions. In Vitro Cell Dev Biol 1993, 29A, 742-748.
61. 61. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995, 80, 179-185.
62. 62. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IAG. Evidence for cell-specific differences in transformation by N-, H-and K-ras. Oncogene 1995, 11, 1639-1647.
63. 63. Roychowdhury DF, Tseng A, Fu KK, Weinberg V, Weidner N. New prognostic factors in nasopharyngeal carcinoma. Cancer 1996, 77, 1419-1426.
64. 64. Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Natl Cancer Inst 1988, 80, 1605-1611.
65. 65. Tokuda Y, Ohnishi Y, Shimamura K. In vitro and in vivo anti-tumour effects of a humanised monoclonal antibody against c-erbB-2 product. Br J Cancer 1996, 73, 1362-1365.
66. 66. Mansour SJ, Matten WT, Hermann AS. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994, 265, 966.
67. 67. Brunet A, Pages G, Pouyssegur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene 1994, 9, 3379-3387.
68. 68. Oldham SM, Clark GJ, Gangarosa LM, Coffey RJ Jr, Der CJ. Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc Natl Acad Sci USA 1996, 93, 6924-6928.
69. 69. Borsum T. Biochemical properties of vascular endothelial cells. Virchows Arch B Cell Pathol 1991, 60, 279-286.
70. 70. Rak JW, Hegmann EJ, Kerbel RS. The role of angiogenesis in tumor progression and metastasis. In Heppner GH, ed. Advances in Molecular and Cell Biology. JAI Press, Inc., 1993, 205-251.
71. 71. Haimovitz-Friedman A, Vlodavsky I, Chaudhuri A, Witte L, Fuks Z. Autocrine effects of fibroblast growth factor in repair of radiation damage in endothelial cells. Cancer Res 1991, 51, 2552-2558.
72. 72. Yamane A, Seetharam L, Yamaguchi S. A new communication system between hepatocytes and sinusoidal endothelial cells in liver through vascular endothelial growth factor and Flt tyrosine kinase receptor family (Flt-1 and KDR/Flk-1). Oncogene 1994, 9, 2683-2690.
73. 73. Krasagakis K, Garbe C, Zouboulis ChC, Orfanos CE. Growth control of melanoma cells and melanocytes by cytokines. In Garbe C, Schmitz S, Orfanos, CE, eds. Skin Cancer: Basic Science, Clinical Research and Treatment. Heidelberg, Springer-Verlag, 1995, 169-182.
74. 74. Claffey KP, Brown LF, del Aguila LF. Expression of vascular permeability factor/vascular endothelial growth factor on melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res 1996, 56, 172-181.
75. 75. Villaschi S, Nicosia RF. Paracrine interactions between fibroblasts and endothelial cells in a serum-free coculture model. Lab Invest 1994, 71, 291-299.
76. 76. Antonelli-Orlidge A, Saunders KB, Smith SR, D'Amore PA. An activated form of transforming growth factor beta is produced by cocultures of endothelial cells and pericytes. Proc Natl Acad Sci USA 1989, 86, 4544-4548.
77. 77. Filmus J, Kerbel RS. Development of resistance mechanisms to the growth inhibitory effects of transforming growth factor-β during tumor progression. Curr Opin Oncol 1993, 5, 123-129.
78. 78. Flaumenhaft R, Abe M, Mignatti P, Rifkin DB. Basic fibroblast growth factor-induced activation of latent transforming growth factor β in endothelial cells: regulation of plasminogen activator activity. J Cell Biol 1992, 118, 901-909.
79. 79. Nicosia RF, Tuszynski GP. Matrix-bound thrombospondin promotes angiogenesis in vitro. J Cell Biol 1994, 124, 183-193.
80. 80. Auerbach R. Interactions between cancer cells and the endothelium. In Orr, S, Weiss L, eds. Microcirculation in Cancer Metastasis. Boca Raton, CRC press, 1991, 169-181.
81. 81. Vernon RB, Sage EH. Between molecules and morphology. Am J Pathol 1995, 147, 873-883.
82. 82. Li L, Nicolson GL, Fidler IJ. Direct in vitro lysis of metastatic tumor cells by cytokine-activated murine vascular endothelial cells. Cancer Res 1991, 51, 245-254.
83. 83. Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Bioch Biophys Acta 1990, 1032, 89-118.
84. 84. Hamada J, Cavanaugh PG, Lotan O, Nicolson GL. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. Br J Cancer 1992, 66, 349-354.
85. 85. Hamada J-I, Cavanaugh PG, Miki K, Nicolson GL. A paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: identification as complement component C3b. Cancer Res 1993, 53, 4418-4423.
86. 86. Nicosia RF, Tchao R, Leighton J. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. Cancer Res 1983, 43, 2159-2166.
87. 87. Nicosia RF, Tchao R, Leighton J. Interactions between newly formed endothelial channels and carcinoma cells in plasma clot culture. Clin Exp Metastasis 1986, 4, 91-104.
88. 88. Ruoslahti E, Reed JC. Anchorage dependence, integrins, and apoptosis. Cell 1994, 77, 477-478.
89. 89. Brooks PC, Montgomery AMP, Rosenfeld M. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79, 1157-1164.
90. 90. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Anti-integrin αvβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995, 96, 1815-1822.
91. 91. Podor TJ, Jirik FR, Loskutoff DJ, Carsom DA, Lotz M. Human endothelial cells produce IL-6. Ann NY Acad Sci 1989, 557, 374-387.
92. 92. Motro B, Itin A, Sachs L, Keshet E. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA 1990, 87, 3092-3096.
93. 93. Tamm I, Kikuchi T, Cardinale I, Krueger JG. Cell-adhesion-disrupting action of interleukin 6 in human ductal breast carcinoma cells. Proc Natl Acad Sci USA 1994, 91, 3329-3333.
94. 94. Sabourin LA, Hawley RG. Suppression of programmed death and G1 arrest in B-cell hybridomas by interleukin-6 is not accompanied by altered expression immediate early response genes. J Cell Physiol 1990, 145, 564-574.
95. 95. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 1996, 271, 736-741.
96. 96. Okamura K, Sato Y, Matsuda T. Endogenous basic fibroblast growth factor-dependent induction of collagenase and interleukin 6 in tumor necrosis factor treated human microvascular endothelial cells. J Biol Chem 1991, 266, 19162-19165.
97. 97. Chiu JJ, Sgagias MK, Cowan KH. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 1996, 2, 215-221.
98. 98. MacDougall J, Kerbel RS. Responsiveness of normal/dysplastic melanocytes and melanoma cells from different lesional stages of disease progression to the growth inhibitory effects of TGF-β. Mol Cell Different 1993, 1, 21-40.
99. 99. Parmiter AH, Nowell PC. Cytogenetics of melanocytic tumors. J Invest Dermatol 1993, 100, 254s-258s.
100. 100. Clark W. Tumor progression and the nature of cancer. Br J Cancer 1991, 64, 631-644.
101. 101. Swope VB, Abdel-Malek Z, Kassam LM, Nordlund JJ. Interleukins 1α and 6 and tumor necrosis factor α are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 1991, 96, 180-185.
102. 102. Lu C, Vickers MF, Kerbel RS. Interleukin-6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. Proc Natl Acad Sci USA 1992, 89, 9215-9219.
103. 103. Kerbel RS. Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer: malignant melanoma as a paradigm. Am J Pathol 1992, 141, 519-524.
104. 104. Filmus J, Zhao J, Buick RN. Over-expression of H-ras oncogene induces resistance to the growth inhibitory action of TGF-β1 and alters the number and type of TGF-β1 receptors in rat intestinal epithelial cell clones. Oncogene 1992, 7, 521-526.
105. 105. Folkman J. What is the role of angiogenesis in metastasis from cutaneous melanoma? Eur J Cancer Clin Oncol 1987, 23, 361-363.
106. 106. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Am J Pathol 1994, 144, 329-336.
107. 107. Rak JW, Hegmann EJ, Lu C, Kerbel RS. Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression. J Cell Physiol 1994, 159, 245-255.
108. 108. Barnhill RL, Levy MA. Regressing thin cutaneous malignant melanomas (≤ 1.0 mm) are associated with angiogenesis. Am J Pathol 1993, 143, 99-104.
109. 109. Gromet MA, Epstein WL, Blois MS. The regressing thin malignant melanoma - a distinctive lesion with metastatic potential. Cancer 1978, 42, 2282-2292.
110. 110. Clark WH, Elder DE, Guerry D. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989, 81, 1893-1904.
111. 111. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80, 879-886.
112. 112. Havrilesky LJ, Hurteau JA, Whitaker RS. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor β. Cancer Res 1995, 55, 944-948.
113. 113. Evan GI. Old cells never die, they just apoptose. Trends Cell Biol 1994, 4, 191-192.
114. 114. Boudreau N, Werb Z, Bissell MJ. Suppression of apoptosis by basement membrane requires three-dimensional tissue organization and withdrawal from the cell cycle. Proc Natl Acad Sci USA 1996, 93, 3509-3513.
115. 115. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86, 353-364.
116. 116. Tsai J-C, Goldman CK, Gillespie GY. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J Neurosurg 1995, 82, 864-873.
117. 117. Frank S, Hubner G, Breier G, Longaker MT, Greenhalgh DG, Werner S. Regulation of vascular endothelial growth fctor expression in cultured keratinocytes. J Biol Chem 1995, 270, 12607-12613.
118. 118. Koolwijk P, van Erck MGM, de Vree WJA. Cooperative effect of TNFα, bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix. Role of urokinase activity. J Cell Biol 1996, 132, 1177-1188.
119. 119. Kolch W, Martiny-Brown G, Kieser A, Marni D. Regulation of the expression of VEGF/VPS and its receptors: role in tumor angiogenesis. Breast Cancer Res Treat 1995, 36, 139-155.
120. 120. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994, 265, 1582-1584.
121. 121. Wizigmann-Voos S, Breier G, Risau W, Plate KH. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic hemangioblastomas. Cancer Res 1995, 55, 1358-1364.
122. 122. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein. Cancer Res 1996, 56, 2299-2301.
123. 123. Schweigerer L, Neufeld G, Friedman J, Abraham JA, Fiddes JC, Gospodarowicz D. Capillary endothelial cells express basic fibroblast growth factor, a mitogen that promotes their own growth. Nature 1987, 325, 257-259.
124. 124. Nomura M, Yamagishi S, Harada S. Possible participation of autocrine and paracrine vascular endothelial growth factors in hypoxia-induced proliferation of endothelial cells and pericytes. J Biol Chem 1995, 270, 28316-28324.
125. 125. Maier JAM, Voulalas P, Roeder D, Maciag T. Extension of the life-span of human endothelial cells by an interleukin-1α antisense oligomer. Science 1990, 249, 1570-1574.
126. 126. May LT, Torcia G, Cozzolino F. Interleukin-6 gene expression in human endothelial cells RNA start sites, multiple IL-6 proteins and inhibition of proliferation. Biochem Biophys Res Commun 1989, 159, 991-997.
127. 127. Maruo N, Morita I, Shirao M, Murota S. IL-6 increases endothelial permeability in vitro. Endocrinology 1992, 131, 710-714.
128. 128. Koch AE, Polverini PJ, Kunkel SL. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258, 1798-1801.
129. 129. Grant D, Kleinman H, Goldberg S. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993, 90, 1937-1941.
130. 130. DiCorleto PE. Cultured endothelial cells produce multiple growth factors for connective tissue cells. Exp Cell Res 1984, 153, 167-172.
131. 131. Bradham DM, Igarashi A, Potter RL, Grotendorst GR. Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991, 114, 1285-1294.
132. 132. DiCorleto PE, Fox PL. Growth factor production by endothelial cells. In Ryan US, ed. Endothelial Cells. Boca Raton, CRC Press Inc., 1990, 51-61.
133. 133. Castellot JJ Jr, Addonizio ML, Rosenberg R, Karnovsky MJ. Cultured endothelial cells produce a heparin like inhibitor of smooth muscle cell growth. J Cell Biol 1981, 90, 372-379.
134. 134. Boes M, Dake BL, Bar RS. Interactions of cultured endothelial cells with TGFbeta, bFGF, PDGF, and IFG-I. Life Sci 1991, 48, 811-821.
135. 135. Yoshizumi M, Kourembanas S, Temizer DH, Cambria RP, Quertermous T, Lee ME. Tumor necrosis factor increases transcription of the heparin-binding epidermal growth factor-like gene in vascular endothelial cells. J Biol Chem 1992, 267, 9467-9469.
136. 136. Quesenberry PJ, Gimbrone MA Jr. Vascular endothelium as a regulator of granulopoiesis: production of colony-stimulating activity by cultured human endothelial cells. Blood 1980, 56, 1060-1067.
137. 137. Wagner CR, Vetto RM, Burger DR. Expression of I-region-associated antigen (Ia) and interleukin 1 by subcultured human endothelial cells. Cell Immun 1985, 93, 91-104.
138. 138. Oka S, Mitsui Y. Growth regulation of vascular cells by cytokines. Nippon Rinsho 1992, 50, 1748-1755.
139. 139. Bussolino F, De Rossi M, Sica A. Murine endothelioma cell lines tranformed by polyoma middle T oncogene as a target for and producers of cytokines. J Immunol 1991, 147, 2122-2129.
140. 140. Lubbert M, Mantovani L, Lindemann A, Mertelsmann R, Herrmann F. Expression of leukemia inhibitory factor is regulated in human mesenchymal cells. Leukemia 1991, 5, 361-365.
141. 141. Broudy VC, Kaushansky K, Harlan JM, Adamson JW. Interleukin 1 stimulates human endothelial cells to produce granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor. J Immunol 1987, 139, 464-468.
142. 142. Peng HB, Rajavashisth TB, Libby P, Liao JK. Nitric oxide inhibits macrophage-colony stimulating factor gene transcription in vascular endothelial cells. J Biol Chem 1995, 270, 17050-17055.
143. 143. Zsebo KM, Yuschenkoff VN, Schiffer S. Molecular endothelial cells and granulopoiesis: interleukin-1 stimulates release of G-CSF and GM-CSF. Blood 1988, 71, 99-103.
144. 144. Suen Y, Chang M, Lee SM, Buzby JS, Cairo MS. Regulation of interleukin-11 protein and mRNA expression in neonatal and adult fibroblasts and endothelial cells. Blood 1994, 84, 4125-4134.
145. 145. Wen D, Rowland A, Derynck R. Expression and secretion of gro/MGSA by stimulated human endothelial cells. EMBO J 1989, 8, 1761-1766.
146. 146. Swerlick RA, Lawley TJ. Role of microvascular endothelial cells in inflammation. J Invest Dermatol 1993, 100, 111S-115S.
147. 147. Nicolson GL, Cavanaugh PG, Inoue T. Differential stimulation of the growth of lung-metastasizing tumor cells by lung (paracrine) growth factors: identification of transferrin-like mitogens in lung tissue-conditioned medium. J Natl Cancer Inst Monographs 1992, 13, 153-161.
148. 148. Hamada J, Cavanaugh PG, Miki K, Nicolson GL. A paracrine migration-stimulating factor for metastatic tumor cells secreted by mouse hepatic sinusoidal endothelial cells: identification as complement component C3b. Cancer Res 1993, 53, 4418-4423.
149. 149. Mazure NM, Chen EY, Yeh P, Laderoute KR, Giaccia AJ. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res 1996, 56, 3436-3440.